Business
IDEAYA Biosciences to Participate in Investor Conferences in March 2022
SOUTH SAN FRANCISCO, Calif., March 1, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 1, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in March 2022.\n\n \n \n \n \n \n \n\n \nGuggenheim 3rd Annual Healthy Altitudes CEO Summit Panel Thursday, March 10 at 9:00am ET\nParticipation by Yujiro Hata, Chief Executive Officer, IDEAYA Biosciences, moderated by Dan Skovronsky, M.D. Ph.D. CSO, Eli Lilly with host Seamus Fernandez, Senior Managing Director and Global Biopharma Analyst, Guggenheim Securities\nOppenheimer Targeted Oncology PanelMonday, March 14, 10:00am ET\nParticipation by Yujiro Hata, Chief Executive Officer, IDEAYA Biosciences, hosted by Kevin DeGeeter Managing Director and Senior Analyst, Biotechnology and Diagnostics, Oppenheimer\n34th Annual Roth ConferenceMonday, March 14, 2022 at 6:00pm ET\nFireside chat with Paul Stone, Chief Financial Officer, IDEAYA Biosciences, hosted by Zegbeh Jallah Ph.D. Managing Director, Research Analyst, Biotechnology Roth Capital Partners\nOppenheimer's 32nd Annual Healthcare Conference Wednesday, March 16, 2022 at 10:40am ET\nPresentation by Yujiro Hata, Chief Executive Officer, IDEAYA Biosciences\nA live audio webcast of the event will be available, as permitted by conference host, at the \"Investors/News and Events/Investor Calendar\" section of the IDEAYA website at https://ir.ideayabio.com/events. A replay of available webcasts will be accessible for 30 days following the live event.\nAbout IDEAYA Biosciences\nIDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. \nForward-Looking Statements\nThis press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentatio...